Preclinical and clinical studies have indicated that somatostatin receptor (sst)–expressing tumors demonstrate higher uptake of radiolabeled sst antagonists than of sst agonists. In 4 consecutive ...

We present an overview of our prospective fibroblast-activation protein inhibitor (FAPI) registry study across a 3-y period, with head-to-head comparison of tumor uptake in 68Ga-FAPI and 18F-FDG PET, ...

Fructose metabolism has been implicated in various diseases, including metabolic disorders, neurodegenerative disorders, cardiac disorders, and cancer. However, the limited availability of a ...

Quantitative 18F-FDG PET is increasingly being recognized as an important tool for diagnosis, determination of prognosis, and response monitoring in oncology. However, PET quantification with, for ...

molecular tumor imaging PET SPECT radionuclide therapy theranostic applications prostate cancer gastrin releasing peptide receptor antagonist The high-density expression of gastrin-releasing peptide ...

The Nuclear Medicine Global Initiative was formed in 2012 by 13 international organizations to promote human health by advancing the field of nuclear medicine and molecular imaging by supporting the ...

Myocardial perfusion SPECT imaging accounts for well over 90% of all myocardial perfusion imaging performed in the United States today. Although clearly superior to the traditional planar technique in ...

The tumor stroma, which accounts for a large part of the tumor mass, represents an attractive target for the delivery of diagnostic and therapeutic compounds. Here, the focus is notably on a ...

This article reviews routine quality-control (QC) procedures for current nuclear medicine instrumentation, including the survey meter, dose calibrator, well counter, intraoperative probe, organ ...

This article presents system performance studies for the Discovery MI PET/CT system, a new time-of-flight system based on silicon photomultipliers. System performance and clinical imaging were ...

Mesoporous silica nanoparticles (MSNs) were explored as a carrier material for the stable isotope 165Ho and, after neutron capture, its subsequent therapeutic radionuclide, 166Ho (half-life, 26.8 h), ...

The incidence of androgen receptor (AR)–negative (AR−) prostate cancer, including aggressive neuroendocrine prostate cancer (NEPC), has more than doubled in the last decade, but its timely diagnosis ...